SFX by Ex Libris Inc.

Title:	Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF
Source:	Blood [0006-4971] Guba, Markus yr:2005

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Dorfleutner, A. "Cross-talk of integrin alpha3beta1 and tissue factor in cell migration." Molecular biology of the cell 15.10: 4416-4425.
description	2.	Guba, M. "Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor." Nature medicine 8.2 (2002): 128-35.
description	3.	Cho, D. "The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer." Clinical cancer research 13.2 (2006): 758-763.
description	4.	Nobeyama, Y. "Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas." International journal of cancer 121.2 (2007): 301-7.
description	5.	Phung, Thuy L L. "Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin." Cancer cell 10.2 (2006): 159-70.
description	6.	Suthanthiran, M. "Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy." Transplantation 73.10: 1565-1572.
description	7.	Klemke, M. "High affinity interaction of integrin alpha4beta1 (VLA-4) and vascular cell adhesion molecule 1 (VCAM-1) enhances migration of human melanoma cells across activated endothelial cell layers." Journal of cellular physiology 212.2 (2007): 368-74.
description	8.	"Le medicament du mois. Everolimus (RAD001/Afinitor) dans le traitement du cancer du rein metastatique." Revue médicale de Liège. 65.4: 212-.
description	9.	Kereveur, A. "Production of tissue factor pathway inhibitor in cardiomyocytes and its upregulation by interleukin-1." Thrombosis and haemostasis 86.5 (2001): 1314-9.
description	10.	Gessler, F. "Knockdown of TFPI-2 promotes migration and invasion of glioma cells." Neuroscience Letters 497.1 (2011): 49-54.
description	11.	Censarek P, Steger G, Paolini C, Hohlfeld T, Gross, P. "Alternative splicing of platelet cyclooxygenase-2 mRNA in patients after coronary artery bypass grafting." Thrombosis and haemostasis 98.6 (2007): 1309-1315.
description	12.	Jiang, Shimei E. "Formation of tissue factor-factor VIIa-factor Xa complex induces activation of the mTOR pathway which regulates migration of human breast cancer cells." Thrombosis and haemostasis 100.1 (2008): 127-33.
description	13.	DeHart, Gregory W. "The role of alpha 3 beta 1 integrin in determining the supramolecular organization of laminin-5 in the extracellular matrix of keratinocytes." Experimental cell research 283.1 (2003): 67-79.
description	14.	Jiang, X. "Formation of tissue factor-factor VIIa-factor Xa complex promotes cellular signaling and migration of human breast cancer cells." Journal of thrombosis and haemostasis 2.1 (2004): 93-101.
description	15.	Nicholson, M L L. "Rapamycin in transplantation: a review of the evidence." Kidney international 59.1 (2000): 3-16.
description	16.	Hurwitz, H. "Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer." The New England journal of medicine 350.23 (2004): 2335-42.
description	17.	Lang, Edward K A. "Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model." International journal of cancer 120.8 (2006): 1803-1810.
description	18.	Dancey, Janet E E. "Therapeutic targets: MTOR and related pathways." Cancer biology & therapy 5.9 (2006): 1065-73.
description	19.	Mackman, N. "Role of tissue factor in hemostasis, thrombosis, and vascular development." Arteriosclerosis, thrombosis, and vascular biology 24.6 (2004): 1015-1022.
description	20.	Kaplan, Rosandra N N. "VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche." Nature 438.7069 (2006): 820-7.